|
Arcturus Therapeutics Holdings Inc. (ARCT) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Arcturus Therapeutics Holdings Inc. (ARCT) Bundle
Engerrado para la precisión, nuestra calculadora DCF (ARCT) le permite evaluar la valoración de Arcturus Therapeutics Holdings Inc. utilizando datos financieros del mundo real, al tiempo que proporciona flexibilidad completa para modificar todos los parámetros esenciales para las proyecciones mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8 | 9.5 | 12.4 | 205.8 | 157.7 | 178.3 | 201.5 | 227.8 | 257.5 | 291.0 |
| Revenue Growth, % | 0 | -54.12 | 29.56 | 1564.82 | -23.33 | 13.03 | 13.03 | 13.03 | 13.03 | 13.03 |
| EBITDA | -24.4 | -70.6 | -201.7 | 13.7 | -24.2 | -110.1 | -124.4 | -140.6 | -158.9 | -179.6 |
| EBITDA, % | -117.47 | -740.56 | -1631.68 | 6.66 | -15.32 | -61.73 | -61.73 | -61.73 | -61.73 | -61.73 |
| Depreciation | .7 | .9 | 1.2 | 1.5 | 3.0 | 8.8 | 10.0 | 11.3 | 12.8 | 14.4 |
| Depreciation, % | 3.29 | 9.25 | 9.65 | 0.74214 | 1.87 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 |
| EBIT | -25.1 | -71.5 | -202.9 | 12.2 | -27.1 | -111.0 | -125.5 | -141.8 | -160.3 | -181.2 |
| EBIT, % | -120.76 | -749.81 | -1641.33 | 5.92 | -17.19 | -62.26 | -62.26 | -62.26 | -62.26 | -62.26 |
| Total Cash | 71.4 | 462.9 | 370.5 | 391.9 | 292.0 | 178.3 | 201.5 | 227.8 | 257.5 | 291.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.2 | 2.1 | 3.4 | 2.8 | 32.1 | 29.1 | 32.9 | 37.2 | 42.1 | 47.5 |
| Account Receivables, % | 10.48 | 22.28 | 27.24 | 1.34 | 20.33 | 16.33 | 16.33 | 16.33 | 16.33 | 16.33 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0.00000809127 | 0 | 0 | 0.000001618254 | 0.000001618254 | 0.000001618254 | 0.000001618254 | 0.000001618254 |
| Accounts Payable | 5.8 | 10.8 | 10.1 | 7.4 | 5.3 | 77.1 | 87.1 | 98.5 | 111.3 | 125.8 |
| Accounts Payable, % | 27.87 | 112.95 | 81.38 | 3.62 | 3.35 | 43.24 | 43.24 | 43.24 | 43.24 | 43.24 |
| Capital Expenditure | -.8 | -1.7 | -3.4 | -7.7 | -2.9 | -19.7 | -22.3 | -25.2 | -28.5 | -32.2 |
| Capital Expenditure, % | -3.93 | -18.26 | -27.56 | -3.75 | -1.84 | -11.07 | -11.07 | -11.07 | -11.07 | -11.07 |
| Tax Rate, % | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 |
| EBITAT | -24.8 | -70.7 | -206.0 | 10.7 | -28.9 | -107.8 | -121.9 | -137.8 | -155.7 | -176.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -21.4 | -66.6 | -210.2 | 2.5 | -60.3 | -44.0 | -127.9 | -144.6 | -163.4 | -184.7 |
| WACC, % | 16.13 | 16.13 | 16.13 | 16.1 | 16.13 | 16.12 | 16.12 | 16.12 | 16.12 | 16.12 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -402.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -192 | |||||||||
| Terminal Value | -1,585 | |||||||||
| Present Terminal Value | -750 | |||||||||
| Enterprise Value | -1,153 | |||||||||
| Net Debt | -262 | |||||||||
| Equity Value | -891 | |||||||||
| Diluted Shares Outstanding, MM | 27 | |||||||||
| Equity Value Per Share | -33.47 |
What You Will Get
- Real ARCT Financial Data: Pre-filled with Arcturus Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Arcturus Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Arcturus Therapeutics' historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Results: View Arcturus’ intrinsic value recalibrated instantly.
- Intuitive Visual Outputs: Dashboard charts showcase valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing Arcturus Therapeutics Holdings Inc. (ARCT) preloaded data.
- 2. Adjust Key Inputs: Modify essential assumptions such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to bolster your strategic decisions.
Why Choose Arcturus Therapeutics Holdings Inc. (ARCT)?
- Innovative Solutions: Cutting-edge technology in RNA medicines tailored for unmet medical needs.
- Robust Pipeline: A diverse range of therapeutic candidates targeting various diseases.
- Expert Team: Led by industry veterans with extensive experience in biotech and pharmaceuticals.
- Strong Partnerships: Collaborations with leading organizations to enhance research and development.
- Commitment to Quality: Adherence to the highest standards in manufacturing and clinical trials.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them using real-world case studies.
- Researchers: Integrate advanced therapeutic models into academic projects or studies.
- Investors: Evaluate your investment strategies and analyze valuation outcomes for Arcturus Therapeutics Holdings Inc. (ARCT).
- Market Analysts: Enhance your analysis with a tailored, ready-to-use financial model specific to the biotech sector.
- Healthcare Entrepreneurs: Understand the methodologies used to assess large biotech firms like Arcturus Therapeutics Holdings Inc. (ARCT).
What the Template Contains
- Pre-Filled DCF Model: Arcturus Therapeutics' financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Arcturus Therapeutics' profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.